Stratec Biomedical AG Company Profile (ETR:SBS)

About Stratec Biomedical AG (ETR:SBS)

Stratec Biomedical AG logoSTRATEC Biomedical AG designs and manufactures solutions for automated processes in the fields of in vitro diagnostics and life sciences. The company operates through two segments, Instrumentation and All Other segments. It offers instrumentation products, such as automated analyzer systems, including THOLOS VMI-100, GEMINI, and GEMINI Combo for use in clinical diagnostics and biotechnology to laboratories, blood banks, and research institutes. The company also develops laboratory data management software, including Aurora Touch, Aurora Vigilant, Aurora AccLaIM, Aurora Stats, Aurora Morpheus, and Aurora Liberty SRImport for laboratories, diagnostic companies, and instrument manufacturers. In addition, it offers a range of optimized solutions for DNA and RNA preparation from various samples for applications in clinical diagnostics and life science research, including genomic DNA, viral RNA and DNA, bacterial DNA, total RNA, DNA fragments and pDNA, universal nucleic acid purification product line, automated sample preparation, enzymes, and reagents; and invests in other companies. Further, the company develops workflow software for networking several analyzer systems. STRATEC Biomedical AG has operations in Germany and other European Union countries, and internationally. The company was formerly known as STRATEC Biomedical Systems AG and changed its name to STRATEC Biomedical AG in April 2011. STRATEC Biomedical AG was founded in 1979 and is headquartered in Birkenfeld, Germany.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: ETR:SBS
  • CUSIP: N/A
  • Web: www.stratec.com/
P/E:
  • Trailing P/E Ratio:
  • P/E Growth:
Profitability:
  • Net Margins: 5.46%
  • Return on Equity: 7.76%
  • Return on Assets: 4.39%
 

Frequently Asked Questions for Stratec Biomedical AG (ETR:SBS)

What is Stratec Biomedical AG's stock symbol?

Stratec Biomedical AG trades on the ETR under the ticker symbol "SBS."

Where is Stratec Biomedical AG's stock going? Where will Stratec Biomedical AG's stock price be in 2017?

5 brokerages have issued 1-year price objectives for Stratec Biomedical AG's stock. Their predictions range from €55.00 to €66.00. On average, they expect Stratec Biomedical AG's stock price to reach €60.00 in the next twelve months. View Analyst Ratings for Stratec Biomedical AG.

Who are some of Stratec Biomedical AG's key competitors?

Who are Stratec Biomedical AG's key executives?

Stratec Biomedical AG's management team includes the folowing people:

  • Fred K. Brueckner, Chairman of the Supervisory Board
  • Marcus Wolfinger, Chairman of the Management Board, Chief Executive Officer
  • Robert Siegle, Director of Finance and Human Resources, Member of the Board of Management
  • Andreas Kuenzel, Director of Investor Relations
  • Claus Vielsack, Member of the Management Board, Director of Product Development
  • Roland Baule, Member of the Supervisory Board
  • Stefanie Remmele, Member of the Supervisory Board


MarketBeat Community Rating for Stratec Biomedical AG (ETR SBS)
Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  18 (Vote Outperform)
Underperform Votes:  17 (Vote Underperform)
Total Votes:  35
MarketBeat's community ratings are surveys of what our community members think about Stratec Biomedical AG and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Stratec Biomedical AG (ETR:SBS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.40)
Consensus Price Target: €60.00
Consensus Price Target History for Stratec Biomedical AG (ETR:SBS)
Price Target History for Stratec Biomedical AG (ETR:SBS)
Analysts' Ratings History for Stratec Biomedical AG (ETR:SBS)
Show:
DateFirmActionRatingPrice TargetDetails
7/27/2017Deutsche Bank AGSet Price TargetNeutral€55.00View Rating Details
7/26/2017Kepler Capital MarketsSet Price TargetBuy€66.00View Rating Details
7/25/2017Warburg ResearchSet Price TargetBuy€62.00View Rating Details
7/25/2017Berenberg BankSet Price TargetNeutral€59.00View Rating Details
7/24/2017Oddo SecuritiesSet Price TargetNeutral€58.00View Rating Details
(Data available from 10/23/2015 forward)

Earnings

Earnings History for Stratec Biomedical AG (ETR:SBS)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Stratec Biomedical AG (ETR:SBS)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Stratec Biomedical AG (ETR:SBS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Stratec Biomedical AG (ETR:SBS)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Stratec Biomedical AG (ETR:SBS)
Latest Headlines for Stratec Biomedical AG (ETR:SBS)
Source:
Loading headlines, please wait.

Social

Social activity is not available for this stock.
This page was last updated on 10/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.